Suzanne Rosenberg’s “Recombinant Bi-specific Cytotoxic Lymphocyte-activating Polypeptides for Tumor Immunotherapy” project submitted to the UMBC Techology Catalyst Fund is funded in full.
Posted: December 4, 2014, 2:44 PM